Anil K. Rengan, MD


Cooper University Health Care Titles

  • Hematologist/Medical Oncologist

Cooper Medical School of Rowan University Titles

  • Assistant Professor of Medicine

Board Certifications

  • American Board of Internal Medicine (Internal Medicine - General)
  • American Board of Internal Medicine (Hematology)
  • American Board of Internal Medicine (Medical Oncology)

Professional Type

Cooper University Physician



Education & Training

Medical SchoolRutgers New Jersey Medical School, Newark, NJ
ResidencyInternal Medicine - Temple University Hospital, Philadelphia, PA
FellowshipHematology/Oncology - Fox Chase Cancer Center, Philadelphia, PA


  • International Society on Thrombosis and Haemostasis
  • American Society of Hematology
  • American Society of Clinical Oncology
  • American Medical Association
  • American College of Physicians


Rengan AK, Denlinger CS. Robust Response to Futibatinib in a Patient With Metastatic FGFR-Addicted Cholangiocarcinoma Previously Treated Using Pemigatinib. J Natl Compr Canc Netw. 2022 Apr 4;20(5):430-435. doi: 10.6004/jnccn.2021.7121. PMID: 35378504.

Rengan AK, Denlinger CS. After gastrointestinal cancer: navigating the transition from active treatment to long-term survivorship. Coping with Cancer Magazine. 2021 Mar;16-17.

Stapor D, Rengan AK, Weiner M, Zhao H, Ali N. Platelet trends are not predictive of heparin induced thrombocytopenia in patients on extra corporeal membrane oxygenation. Blood. 2018 Nov;132(Supplement 1):3767